Christoph Lengauer is a drug hunter, having contributed to the development of ten drugs to date. As a principal investigator at the Vogelstein lab, Johns Hopkins University, he helped identify several cancer driver genes, some of which are targets of approved drugs. After heading up drug discovery departments at Sanofi and Novartis, he moved into biotech, cofounding Thrive, Celsius Therapeutics and MOMA Therapeutics before becoming chief scientific officer of Blueprint Medicines. In 2022 he cofounded Curie.Bio, a founder-focused venture capital firm that offers therapeutics startups mentorship as well as seed capital. They raised over $500m for their first fund.
As well as a joining as a non-executive director on the Cancer Research Horizons board, Christoph is also the inaugural chair of the Therapeutic Innovation board.